Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy

Aim. To study clinical, functional, morphological and pharmacological features of hepatic pathology in patients with non-alcohol hepatic steatosis (NAHS), combined with atherogenic dyslipidemia (ADL) and/or insulin resistance (IR).Material and methods. The study included 240 patients with NAHS: 100...

Full description

Saved in:
Bibliographic Details
Main Authors: L. B. Lazebnik, L. A. Zvenigorodskaya, N. V. Melnikova, E. G. Egorova, S. G. Khomeriki
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2009-06-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1449
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849342244415340544
author L. B. Lazebnik
L. A. Zvenigorodskaya
N. V. Melnikova
E. G. Egorova
S. G. Khomeriki
author_facet L. B. Lazebnik
L. A. Zvenigorodskaya
N. V. Melnikova
E. G. Egorova
S. G. Khomeriki
author_sort L. B. Lazebnik
collection DOAJ
description Aim. To study clinical, functional, morphological and pharmacological features of hepatic pathology in patients with non-alcohol hepatic steatosis (NAHS), combined with atherogenic dyslipidemia (ADL) and/or insulin resistance (IR).Material and methods. The study included 240 patients with NAHS: 100 with DL but no IR; 78 — with IR but no DL; 14 — with Type 2 diabetes mellitus (DM-2), IR and DL; 48 — without DL or IR (controls). All participants underwent standard clinical examination, blood biochemistry and hepatitis virus marker assessment, oral glucose tolerance and HOMA test, abdominal ultrasound and hepatic puncture biopsy.Results. NAHS clinical course was non-specific. Cytolysis syndrome activity was maximal in DM-2 patients. All patients had cholestasis syndrome manifestations, maximal in IR individuals. Hepatic morphology was characterized by large-drop fat dystrophy, inflammation and fibrosis. In patients with disturbed carbohydrate and lipid metabolism, hepatocyte nuclear changes and nuclear polymorphism were observed, respectively. In participants receiving a combination of statins and ezetimibe, blood lipid profile improved at the second week of the treatment. IR patients received metformin, with positive dynamics of hepatic morphology and function.Conclusion. Despite no clinical differences between NAHS patients with ADL and IR, the latter are characterized by more aggressive morphological changes. Differentiated ethiotropic therapy of NAHS should take ADL and IR presence into account.
format Article
id doaj-art-7ce827398b03452fb06b3cc0922ba14c
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 2009-06-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-7ce827398b03452fb06b3cc0922ba14c2025-08-20T03:43:27Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-06-018369771159Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapyL. B. Lazebnik0L. A. Zvenigorodskaya1N. V. Melnikova2E. G. Egorova3S. G. Khomeriki4Central Research Institute of GastroenterologyCentral Research Institute of GastroenterologyCentral Research Institute of GastroenterologyCentral Research Institute of GastroenterologyCentral Research Institute of GastroenterologyAim. To study clinical, functional, morphological and pharmacological features of hepatic pathology in patients with non-alcohol hepatic steatosis (NAHS), combined with atherogenic dyslipidemia (ADL) and/or insulin resistance (IR).Material and methods. The study included 240 patients with NAHS: 100 with DL but no IR; 78 — with IR but no DL; 14 — with Type 2 diabetes mellitus (DM-2), IR and DL; 48 — without DL or IR (controls). All participants underwent standard clinical examination, blood biochemistry and hepatitis virus marker assessment, oral glucose tolerance and HOMA test, abdominal ultrasound and hepatic puncture biopsy.Results. NAHS clinical course was non-specific. Cytolysis syndrome activity was maximal in DM-2 patients. All patients had cholestasis syndrome manifestations, maximal in IR individuals. Hepatic morphology was characterized by large-drop fat dystrophy, inflammation and fibrosis. In patients with disturbed carbohydrate and lipid metabolism, hepatocyte nuclear changes and nuclear polymorphism were observed, respectively. In participants receiving a combination of statins and ezetimibe, blood lipid profile improved at the second week of the treatment. IR patients received metformin, with positive dynamics of hepatic morphology and function.Conclusion. Despite no clinical differences between NAHS patients with ADL and IR, the latter are characterized by more aggressive morphological changes. Differentiated ethiotropic therapy of NAHS should take ADL and IR presence into account.https://cardiovascular.elpub.ru/jour/article/view/1449non-alcohol hepatic steatosisinsulin resistanceatherogenic dyslipidemialipid-lowering therapy
spellingShingle L. B. Lazebnik
L. A. Zvenigorodskaya
N. V. Melnikova
E. G. Egorova
S. G. Khomeriki
Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
Кардиоваскулярная терапия и профилактика
non-alcohol hepatic steatosis
insulin resistance
atherogenic dyslipidemia
lipid-lowering therapy
title Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
title_full Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
title_fullStr Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
title_full_unstemmed Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
title_short Atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis: comparison, contrast, and differentiated therapy
title_sort atherogenic dyslipidemia and insulin resistance associated with nonalcohol hepatic steatosis comparison contrast and differentiated therapy
topic non-alcohol hepatic steatosis
insulin resistance
atherogenic dyslipidemia
lipid-lowering therapy
url https://cardiovascular.elpub.ru/jour/article/view/1449
work_keys_str_mv AT lblazebnik atherogenicdyslipidemiaandinsulinresistanceassociatedwithnonalcoholhepaticsteatosiscomparisoncontrastanddifferentiatedtherapy
AT lazvenigorodskaya atherogenicdyslipidemiaandinsulinresistanceassociatedwithnonalcoholhepaticsteatosiscomparisoncontrastanddifferentiatedtherapy
AT nvmelnikova atherogenicdyslipidemiaandinsulinresistanceassociatedwithnonalcoholhepaticsteatosiscomparisoncontrastanddifferentiatedtherapy
AT egegorova atherogenicdyslipidemiaandinsulinresistanceassociatedwithnonalcoholhepaticsteatosiscomparisoncontrastanddifferentiatedtherapy
AT sgkhomeriki atherogenicdyslipidemiaandinsulinresistanceassociatedwithnonalcoholhepaticsteatosiscomparisoncontrastanddifferentiatedtherapy